Tevogen.AI expands Microsoft, Databricks ties for cancer model beta

Tevogen Bio Holdings Inc. (NASDAQ: TVGN) announced its artificial intelligence unit Tevogen.AI is expanding collaboration with Microsoft Corp. (NASDAQ: MSFT) and Databricks to develop the beta version of its PredicTcell model with oncology applications.

The company said it is curating an oncology-focused dataset using the Databricks Data Intelligence Platform, which will be combined with its existing virology dataset to improve the accuracy of the PredicTcell model's alpha version.

The development builds on Tevogen.AI's recently published international patent application (WO 2025/129197) that describes machine learning systems for predicting immunologically active peptides used in targeted therapies for cancers and infectious diseases.

"Oncology represents one of the most impactful areas for AI in drug discovery, given the complexity of the disease and the limited availability of high-quality datasets," said Mittul Mehta, Chief Information Officer and Head of Tevogen.AI.

The company said Tevogen.AI will explore external market opportunities as a potential revenue source and develop enhanced analytics and visualization tools for the PredicTcell model to support internal research and development teams.

The beta version aims to incorporate oncology targets to enhance the model's accuracy and diversity, according to the press release statement.

You May Also Be Interested In